 |
US's popularity as the market for first launch grows, Tufts finds
Thursday 20 November 2008
Nancy Faigen - Assistant US Editor
The number of new drugs that are marketed first in the US continues to climb, a recent analysis by Boston-based Tufts Center for the Study of Drug Development found.
During 2005-07, the most recent period for which information was available, the number of approved NCEs marketed first in the US reached an all-time high of 75%, the analysis found. This was a marked change from a low of 20% during the 1987-90 period. Around 1996-98, it had been 50%...
Login to view the full article
- Not a subscriber? Request a FREE trial
- Subscribe to Scrip
- Email to a friend
Comments
No Comments Yet
About Scrip
Scrip World Pharmaceutical News provides you with high quality news coverage of pharma and biotech and also gives you strategic data and analysis.
Benefits include:
›› Daily email headlines
›› Searchable news
archive
›› Weekly copies of Scrip
›› Bespoke Scrip supplements
›› Plus the Scrip Yearbook
and Scrip League Tables
Scrip Awards 2008
The best and brightest of the pharmaceutical and biotech industries were celebrated at a glittering ceremony in London at the 2008 Scrip Awards.
Read the full story
Scrip Directory
Scrip Directory 2008
Search over 20,000 international contacts and access potential business opportunities
© Informa plc. All rights reserved. This site is owned and operated by Informa plc ("Informa") whose registered office is
Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
